Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

NCT05492123 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Uterine Cervical Neoplasms

Interventions

DRUG: Nivolumab 40 mg in 4 ml Injection
DRUG: Ipilimumab 200 MG in 40 ML Injection
RADIATION: Chemoradiation

Sponsor

Hospital Israelita Albert Einstein

Collaborators

[object Object]
[object Object]